Overview

Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG

Status:
Active, not recruiting

Trial end date:
2023-05-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Carboplatin
Dabrafenib
Trametinib
Vincristine